The first study to provide evidence of the efficacy of targeting both CTLA-4 (ipilimumab) and PD-1 (nivolumab) in advanced HCC was the phase I/II CheckMate 040.76 The gene discussed is CTLA4; the disease is hepatocellular carcinoma.